Tackling drug-resistant tuberculosis in Europe

The Lancet  
Jan 28, 2012  Volume 379  Number 9813  p287 – 384  e20 – 26

Tackling the spread of drug-resistant tuberculosis in Europe
Ibrahim Abubakar, Masoud Dara, Davide Manissero, Alimuddin Zumla

Multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis have become an important health problem in many countries of the WHO European region and currently threaten global efforts to control tuberculosis.1–4 About 81 000 (18·4%) of the 440 000 patients worldwide with MDR tuberculosis live in this region.2 The highest rates occur predominantly in eastern Europe; however, population movement means that drug-resistant tuberculosis is a priority public health issue for all European countries.